Literature DB >> 1695240

Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein.

N Kerlero de Rosbo1, P Honegger, H Lassmann, J M Matthieu.   

Abstract

A monoclonal antibody (8-18C5) directed against myelin/oligodendrocyte glycoprotein (MOG) induced demyelination in aggregating brain cell cultures. With increasing doses of anti-MOG antibody in the presence of complement, myelin basic protein (MBP) concentration decreased in a dose-related manner. A similar, albeit less pronounced, effect was observed on specific activity of 2',3'-cyclic nucleotide 3'-phosphohydrolase. In the absence of complement, anti-MOG antibody did not induce detectable demyelination. In contrast to the effect of anti-MOG antibody and as expected, anti-MBP antibody did not demyelinate aggregating brain cell cultures in the presence of complement. These results provide additional support to the suggestion that MOG, a quantitatively minor myelin component located on the external side of the myelin membrane, is a good target antigen for antibody-induced demyelination. Indeed, they show that a purified anti-MOG antibody directed against a single epitope on the glycoprotein can produce demyelination, not only in vivo as previously shown, but also in cultures. Such an observation has not been made with polyclonal antisera raised against purified myelin proteins like MBP and proteolipid protein, the major protein components of the myelin membrane, or myelin-associated glycoprotein. These observations may have important implications regarding the possible role of anti-MOG antibodies in demyelinating diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695240     DOI: 10.1111/j.1471-4159.1990.tb04173.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  26 in total

1.  The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement.

Authors:  S J Piddlesden; H Lassmann; F Zimprich; B P Morgan; C Linington
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

2.  Degradation products of myelin-oligodendrocyte-associated proteins in a light CNS subcellular fraction.

Authors:  H Persson
Journal:  Neurochem Res       Date:  1991-10       Impact factor: 3.996

Review 3.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

4.  KIR2DL4-HLAG interaction at human NK cell-oligodendrocyte interfaces regulates IFN-γ-mediated effects.

Authors:  P P Banerjee; L Pang; S S Soldan; S M Miah; A Eisenberg; S Maru; A Waldman; E A Smith; Y Rosenberg-Hasson; D Hirschberg; A Smith; D V Ablashi; K S Campbell; J S Orange
Journal:  Mol Immunol       Date:  2018-11-24       Impact factor: 4.407

5.  Physical mapping of the human and mouse MOG gene at the distal end of the MHC class Ib region.

Authors:  D Pham-Dinh; E P Jones; G Pitiot; B Della Gaspera; P Daubas; J Mallet; D Le Paslier; K Fischer Lindahl; A Dautigny
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

Review 6.  Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis.

Authors:  B G van Engelen; D J Miller; K D Pavelko; O R Hommes; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

7.  Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

Authors:  N Kerlero de Rosbo; R Milo; M B Lees; D Burger; C C Bernard; A Ben-Nun
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

8.  Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex.

Authors:  D Pham-Dinh; M G Mattei; J L Nussbaum; G Roussel; P Pontarotti; N Roeckel; I H Mather; K Artzt; K F Lindahl; A Dautigny
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

Review 9.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 10.  Novel oligodendrocyte transmembrane signaling systems. Investigations utilizing antibodies as ligands.

Authors:  C A Dyer
Journal:  Mol Neurobiol       Date:  1993       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.